Background: Although depression is often reported in prostate cancer patients, some tests of depression omit the somatic criteria that are listed for Major Depressive Episode, arguing that these may be confounded by the cancer itself. However, this omission may be challenged in terms of the particular somatic symptoms that have been associated with prostate cancer. Therefore, the present study investigated the relative contribution to total depression scores made by the somatic criteria for Major Depressive Episode that were not caused by prostate cancer. Patients and Methods:491 prostate cancer patients completed the Zung Self-Rating Depression Scale. Data were analysed to compare the predictive power of 5 subsets of depression on patients' total depressive scores. Results: Somatic symptoms were the most powerful predictor of total depression scores, followed by anhedonia and depressed mood, with similar findings for depression clinical status. Emotional symptoms and cognitive confusion were not significant predictors of total depression scores but did predict depression clinical status. Conclusion: Valid and reliable assessment of depression and selection of appropriate treatment options in prostate cancer patients requires consideration of somatic items which match the DSM-IV-TR criteria for Major Depressive Episode.

1.
Kunkel EJS, Bakker JR, Myers RE, Oyesanmi O, Gomella LG: Biopsychosocial aspects of prostate cancer. Psychosomatics 2000;41:85-94.
2.
Bill-Axelson A, Garmo H, Nyberg U, Lamb M, Bratt O, Stattin P, Adolfsson J, Steineck G: Psychiatric treatment in men with prostate cancer - results from a nation-wide, population-based cohort study Eur J Cancer 2011;47:2195-2201.
3.
Johansson E, Steineck G, Holmberg L, ohansson J, Nyberg T, Ruutu M, Bill-Axelson A: Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian prostate cancer group-4 randomised trial. Lancet Oncol 2011;12:891-899.
4.
Jayadevappa R, Malkowicz S, Chhatre S, Johnson J, Gallo J: The burden of depression in prostate cancer. Psychooncology 2012;21:1338-1345.
5.
APA: Diagnostic and Statistical Manual of Mental Disorders (4th ed, text revision). Washington, DC, American Psychiatric Association, 2000.
6.
Zigmond A, Snaith R: The hospital anxiety and depression scale. Acta Psychiatrica Scandinavia 1983;67:361-370.
7.
Sharpley C, Bitsika V: Four potential criteria for deciding when to use antidepressants or psychotherapy for unipolar depression-a literature review. Int J Psychiatry Clin Pract 2011;15:2-11.
8.
Mishel MH, Belyea M, Germino B, Stewart J, Bailey D Jr, Robertson C, Mohler J: Helping patients with localized prostate carcinoma manage uncertainty and treatment side effects: nurse-delivered psychoeducational intervention over the telephone. Cancer 2002;94:1854-1866.
9.
Stege R: Potential side-effects of endocrine treatment of long duration in prostate cancer. Prostate 2000;10(suppl):38-42.
10.
Dearnaley D, Khoo V, Norman A, Meyer L, Nahum A, Tait D, Yarnold J, Horwich A: Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999;353:267-272.
11.
Zung W: A self-rating depression scale. Arch Gen Psychiatry 1965;12:63-70.
12.
Sharpley C, Bitsika V, Christie D: Understanding the causes of depression among prostate cancer patients: development of the effects of prostate cancer on lifestyle questionnaire. Psychooncology 2009;18:162-168.
13.
Sharpley C, Bitsika V, Christie D: Positive (but not negative) punishment predicts anxiety and depression among prostate cancer patients: an exploration of the behaviour analytic model of depression. Behaviour Change 2009;26:225-234.
14.
Sharpley C, Bitsika V, Christie D: ‘Why I feel bad': refinement of the effects of prostate cancer upon lifestyle questionnaire and an initial exploration of its links with anxiety and depression among prostate cancer patients. Psychooncology 2010;19:839-846.
15.
Sharpley C, Bitsika V, Christie D: Incidence and nature of anxiety-depression comorbidity in prostate cancer patients. J Mens Health 2010;7: 125-134.
16.
Sharpley C, Bitsika V, Christie D: How prostate cancer patients cope: evaluation and refinement of the prostate cancer patients' coping strategies scale. J Men's Health 2012;9:10-18.
17.
DeJonge J, Baneke J: The Zung self-rating depression scale: a replication study on reliability, validity and prediction. Psychological Reports 1989;64:833-834.
18.
Gabrys J, Peters K: Reliability, discriminant and predictive validity of the zung self-rating depression scale. Psychological Reports 1985;57:1091-1096.
19.
Schaefer A, Brown J, Watson C, Plenel D, DeMotts J, Howard M, Petrik N, Ballweg B: Comparison of the validities of the Beck, Zung and MMPI depression scales. J Consult Clin Psychol 1985;53:415-418.
20.
Sharpley C, Christie D: An analysis of the psychometric structure and frequency of anxiety and depression in Australian men with prostate cancer. Psychooncology 2007;16:660-667.
21.
Zung W: From art to science: the diagnosis and treatment of depression. Arch Gen Psychiatry 1973;29:328-337.
22.
Tabachnick B, Fidell L: Using Multivariate Statistics (5th ed). NY, Pearson, 2007.
23.
Anastasi A: Psychological Testing (5th ed). NY, Collier Macmillan, 1982.
24.
Barsky A, Orav J, Bates D: Somatization increases medical utilization and costs independent of psychiatric and medical comorbidity. Arch Gen Psychiatry 2005;62:903-910.
25.
Papakostas G, Petersen T, Denninger J: Somatic symptoms in treatment-resistant depression. Psychiatry Res 2003;118:39-45.
26.
Klengel T, Heck A, Pfister H, Brückl T, Hennings J, Menke A, Czamara D, Müller-Myhsok B, Ising M: Somatization in major depression - clinical features and genetic associations. Acta Psychiatrica Scandinavia 2011;124:317-328.
27.
Ostergaard S, Jensen S, Bech P: The heterogeneity of the depressive syndrome: when numbers get serious. Acta Psychiatrica Scandinavia 2011;124: 495-496.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.